Moffitt logo

Clinical Trials Search

Clinical Trial 19197

Cancer Type: Malignant Hematology
Interventions:CC-5013 (Lenalidomide); Elotuzumab; Lenalidomide (Revlimid)

Study Type: Treatment
Phase of Study: Phase II
Investigators:

  • Melissa Alsina

Call 813-745-6100
or 1-800-679-0775
Overview

Study Title

A Randomized Parallel Phase 2 Study of Elotuzumab plus Lenalidomide (Elo/Rev) for the Treatment of Serologic Relapse/Progression while on Lenalidomide Maintenance for Multiple Myeloma

Summary

The purpose of this study is determine Time-to-Progression with elotuzumab plus lenalidomide when elotuzumab is added to multiple myeloma participants with serologic relapse/progression while receiving lenalidomide maintenance for each study arm.

Objective

Primary Objective: Progression free survival with elotuzumab plus lenalidomide when elotuzumab is added to multiple myeloma patients with serologic relapse/progression while receiving lenalidomide maintenance for each cohort. Secondary Objectives: 1.) Overall response rate (ORR) with elotuzumab and lenalidomide for each cohort. 2.) Minimum response (MR) or better rate with elotuzumab and lenalidomide for each cohort. 3.) Time to next treatment (TTNT) for each cohort. 4. ) Comparison of clinical outcomes (cohort A versus B). 5.) Fc y RIIIa receptor polymorphisms (homozygous for high-affinity V (VV) allele vs. low affinity F (FF) allele). 6.) Determine effect of elotuzumab on phenotypic characteristics of the immune infiltrate and correlate with therapeutic efficacy of elotuzumab.

Inclusion Criteria

  • Patients with multiple myeloma who demonstrate evidence of serologic relapse/progression while on lenalidomide maintenance given as part of first line therapy (including upfront high-dose chemotherapy followed by autologous hematopoietic cell transplantation (HCT)) without symptomatic relapse/progression. Lenalidomide maintenance is defined as single agent lenalidomide therapy of any doses up to 10 mg PO daily for up to 28 days (28-day cycle).
  • Male or female patients aged ≥ 18 years old
  • Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
  • Measurable disease as outlined in protocol guidelines
  • Participants must meet laboratory criteria as outlined in protocol guidelines

  • Exclusion Criteria

  • Prior elotuzumab
  • Patients with clinical relapse/progression as per the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma defined as one or more of the following criteria: Development of new soft tissue plasmacytomas or bone lesions (osteoporotic fractures do not constitute progression); Definite increase in the size of existing plasmacytomas or bone lesions. A definite increase is defined as a 50% (and ≥1 cm) increase as measured serially of the measurable lesion; Hypercalcaemia (>11 mg/dL); Decrease in hemoglobin of ≥2 g/dL not related to therapy or other non-myeloma-related conditions; Rise in serum creatinine by 2 mg/dL or more from the start of the therapy and attributable to myeloma; Hyperviscosity related to serum paraprotein
  • Women who are pregnant or breast feeding or women of childbearing potential (WOCBP) not using an effective method of birth control. Women of childbearing potential must have a negative serum pregnancy testing within 7 days prior to the administration of drug.
  • Male patients whose sexual partners are WOCBP not using effective birth control
  • Patients with a prior malignancy with in the last 5 years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix)
  • Patients with known positivity for human immunodeficiency virus (HIV)) or hepatitis C; baseline testing for HIV and hepatitis C is not required
  • Patients with a diagnosis of POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) or plasma cell leukemia (> 2.0 × 10^9/L circulating plasma cells by standard differential)